Six Years and a Blank Prescription Pad: Where the Real Evidence Sits in the Ruti Aga File

The loudest thing in the six-year sanction document is not the name of a banned substance. It is a prescription. The person who wrote the medication for Ruti Aga was a member of her own family, with no medical registration. The pad it was written on reportedly came from a clinic that has since flatly stated it never had such a pad in circulation. A marathon career stopped on a name placed where a signature belonged, and the name was not a doctor's.

The first thing this file shows is what it lacks. The half marathon at which the sample was collected has no name. No time. No indication whether the sample was urine or blood. No decision date, only an effective date of 10 September. Without those four blanks filled, neither the athlete's position nor the race's position can be measured.

In 2026, at sixteen, I opened a spreadsheet instead of watching highlight clips. The same 2026 race appeared as 10.4 in one clipping and 10.47 in another, and nobody had reconciled them. Four months and 140 marks later, I had a rule I still follow: every number carries a timing method, a source and a confidence level. The numbers are clean; the people who keep them are not. The Aga file stops me at exactly that point. Methylprednisolone is an anti-inflammatory, and a marathoner with a knee complaint is a textbook candidate. The document that was supposed to make that legitimate is now the central charge.

Ruti Aga is 32, Ethiopian, and her headline result is the 2026 Tokyo Marathon title. Around it sit three World Marathon Major runner-up finishes. That profile places her in the second tier of the elite — a reliable podium athlete, not the athlete the event was built around. The economics of that tier matter. A superstar earns from global sponsorship; this tier earns from appearance fees and podium bonuses. Every race is an invoice, and where the invoice lives, medical support often drifts into personal entourages rather than licensed team physicians.

In March she won a half marathon in China. The time was not disclosed, the race name is not in the material I have. That is a reporting gap, not a conspiracy — but the gap is informative. A label-level road race in that tier runs on appearance fees, and its testing footprint is set by the local anti-doping body plus targeted Athlete Integrity Unit work, not by the race's commercial profile. That is the thinnest-surveillance zone a mid-tier elite can enter: high fee, low monitoring.

She was tested after the win. Methylprednisolone was found. A provisional suspension followed from 10 September, then a six-year ban, four years of which come from tampering with documents. No prior sanction appears in the published account, which makes the paperwork, not repeat offending, the driver of the total.

Glucocorticoids are prohibited in competition via injectable, oral and rectal routes, and permitted out of competition with proper clearance. The case is about timing, not the drug. A documented out-of-competition injection is a defensible medical story; a detectable in-competition presence is not. From years of watching track and road racing, I would add a mechanics note: a marathoner's knee pain is the arithmetic of thousands of foot strikes, particularly patellofemoral load and eccentric stress on descents. Nobody invents that pain. Her peak marks also sit inside the first carbon-plate generation, so any comparison needs the method reconciled first.

The injury explanation is credible. The fatal step was the paper chain built around it: a prescription written by a relative with no registration, on a pad from a former workplace whose clinic denies it ever existed. The sanctioning logic treats the cover-up as the dominant offence. I went looking for a missing prescription and found a silent medical channel. In the Ethiopian high-altitude pipeline, a personal coach and an agent-run race calendar are normal; licensed team physicians with TUE literacy do not always scale at the same rate. That is a supply-chain description, not a national critique.

The number that matters now is not a time but an annulment. The March result goes — title, prize money, ranking points. The 2026 Tokyo title survives. I cannot publish the race name, the winning time or the prize money, because I do not have the source documents, and a gap gets labelled as a gap. But the gap is itself a finding: a six-year ruling whose basic competition and sample data are not public cannot be placed in any future dataset. The archive hole should have been filled by now.

Age 32 plus six years is a return at 38, outside the competitive and testing system, with the elite training and agent ecosystem gone. The financial arithmetic is harsher still: appearance fees and podium bonuses dominate this tier's income, so the sanction is close to total rather than marginal. My own beat offers the mirror image. In the athletics budget I audit in Dhaka, out-of-competition testing appears in no line item, and eight divisional headquarters still have no synthetic track. There, a forged prescription would never be caught, because the catching machine does not exist.

The obvious reading — star caught, ban issued, story closed — misses the structure. The system caught the paperwork, not the pipeline. Forged documents are physical objects and therefore catchable; informal entourage medicine keeps no records and therefore is not. Equally, the missing race details are a reporting limit, not evidence of concealment, and no single agent or coach is the villain. A third-tier race pays the appearance fee but does not pay for medical governance, and that unpaid cost lands on the athlete, who solves it with the most available person in the family.

Next March another half marathon will be run and another appearance fee will change hands. The question is who signs the medical form: the local organiser, or the athlete's entourage. If the answer is the second, Ruti Aga's six years are not a punishment. They are a sample nobody read.